What is the Share Price of Marksans Pharma Ltd?
- Answer Field
-
The share price of Marksans Pharma Ltd for NSE is ₹ 259.25 and for BSE is ₹ 258.85.
BAJAJ BROKING
Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply
As of the latest trading session, Marksans Pharma share price is currently at ₹ 259.25, which is down by ₹ -0.70 from its previous closing. Today, the stock has fluctuated between ₹ 250.10 and ₹ 260.00. Over the past year, Marksans Pharma has achieved a return of 63.44 %. In the last month alone, the return has been 9.20 %. Read More...
Particulars | MAR 2025 (Values in Cr) |
---|---|
Revenue | 299.36 |
Operating Expense | 257.27 |
Net Profit | 37.59 |
Net Profit Margin (%) | 12.55 |
Earnings Per Share (EPS) | 0.83 |
EBITDA | 58.39 |
Effective Tax Rate (%) | 24.66 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.36 | 27.76 | 1.99 | 278.64 | 34.11 / 77.70 |
BLISS GVS PHARMA LTD | 149.35 | 18.67 | 1.49 | 1573.70 | 101.00 / 184.95 |
CIPLA LTD | 1505.40 | 23.06 | 3.89 | 121589.70 | 1310.05 / 1702.00 |
FERMENTA BIOTECH LIMITED | 338.10 | 12.94 | 2.74 | 995.06 | 163.00 / 449.00 |
Company Name | Price | P/E | P/B | Market Cap | 52 Week Low/High |
---|---|---|---|---|---|
AMBALAL SARABHAI ENTERPRISES L | 36.36 | 36.36 | 5.74 | 278.64 | 34.11 / 77.70 |
AMRUTAJAN HEALTH LTD | 697.60 | 39.68 | 6.17 | 2016.81 | 548.05 / 861.40 |
ASTRAZENECA PHARMA IND LT | 10524.65 | 150.31 | 34.15 | 26311.63 | 6160.25 / 10653.05 |
BLISS GVS PHARMA LTD | 149.35 | 22.80 | 1.48 | 1573.70 | 101.00 / 184.95 |
Particulars | Sep 2024 (₹ in Cr) | Jun 2024 (₹ in Cr) | Mar 2024 (₹ in Cr) | Dec 2023 (₹ in Cr) | Sep 2023 (₹ in Cr) |
Revenue | 308.63 | 254.53 | 225.20 | 241.36 | 204.67 |
Operating Expense | 263.65 | 220.38 | 198.98 | 208.09 | 176.10 |
Net Profit | 63.20 | 32.02 | 32.99 | 25.29 | 31.29 |
Net Profit Margin (%) | 20.47 | 12.58 | 14.64 | 10.47 | 15.28 |
Earnings Per Share (₹) | 1.39 | 0.71 | 0.73 | 0.56 | 0.69 |
EBITDA | 83.64 | 49.42 | 46.09 | 43.30 | 53.23 |
Effective Tax Rate (%) | 17.19 | 24.30 | 14.08 | 26.90 | 29.68 |
Key Highlights:
Particulars | Mar 2024 (₹ in Cr) | Mar 2023 (₹ in Cr) |
Revenue | 853.27 | 732.00 |
Operating Expense | 743.46 | 650.23 |
Net Profit | 133.76 | 112.65 |
Net Profit Margin (%) | 15.67 | 15.39 |
Earnings Per Share (₹) | 2.95 | 2.50 |
EBITDA | 202.01 | 180.52 |
Effective Tax Rate (%) | 22.18 | 20.50 |
Key Highlights:
Particulars | Ex-Date | Record Date |
Dividend per Share (₹) | 07 Jun, 2023 | 07 Jun, 2023 |
Dividend Yield (%) | 0.5 | Equity Shares |
Key Highlights:
Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005. The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Company's research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai.
In 2004-05, the Company amalgamated with M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited) pursuant to High Court order dated 19th August, 2005. As provided in the approved Scheme of Amalgamation, necessary shares were issued to the shareholders of the M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited).
The Company acquired majority stake in Nova Pharmaceuticals Australasia Private Limited in 2005; further, it acquired two companies, Bell Sons & Company (Druggists) Limited and Relonchem Limited in the UK in 2008. The Company received first ANDA approval in the USA in 2011. It acquired Time-Cap Laboratories Inc. in the US in 2015.
The Company launched the CNS-Cerebella division in FY 2017-18. It launched soft gelatin capsules, a niche category, Launched two products and received CRL for 4 ANDAs for approval with the USFDA.
The Company commissioned a new R&D center at Navi Mumbai, apart from one in Goa in 2019-20. Access Healthcare for Medical Products LLC, a Dubai-based front-marketing and promotion company was acquired in June, 2022.
In 2023-24, Company acquired the business unit of Tevapharm India Private Limited relating to the manufacture and supply of pharmaceutical formulations in Verna, Goa as a going concern via slump sale in April, 2023.
The share price of Marksans Pharma Ltd for NSE is ₹ 259.25 and for BSE is ₹ 258.85.
The market cap of Marksans Pharma Ltd for NSE is ₹ 11,748.27 Cr. and for BSE is ₹ 11,730.14 Cr. as of now.
The 52 Week High and Low of Marksans Pharma Ltd for NSE is ₹ 358.70 and ₹ 155.46 and for BSE is ₹ 358.50 and ₹ 155.55.
You can trade in Marksans Pharma Ltd shares with Bajaj Broking by opening a Demat Account.
The 1 year returns on the stock has been 63.44%.
Marksans Pharma Ltd share price is for NSE ₹ 259.25 & for BSE ₹ 258.85 as on Jun 13 2025 03:30 PM.
The market cap of Marksans Pharma Ltd for NSE ₹ 11,748.27 & for BSE ₹ 11,730.14 as on Jun 13 2025 03:30 PM.
As on Jun 13 2025 03:30 PM the price-to-earnings (PE) ratio for Marksans Pharma Ltd share is 62.45.
As on Jun 13 2025 03:30 PM, the price-to-book (PB) ratio for Marksans Pharma Ltd share is 30.52.
You can trade in Marksans Pharma Ltd shares with Bajaj Broking by opening a demat account.
To buy Marksans Pharma Ltd shares on the Bajaj Broking app, follow these steps:
• Login to the Bajaj Broking App
• Click on the Search Icon
• Search “Marksans Pharma Ltd”
• Click on the BUY icon
• Place a buy order specifying the desired quantity of shares.
• Click BUY again to complete the purchase
No results found